Summary & Overview
HCPCS J2850: Secretin Injection, Synthetic Human, 1 Microgram
HCPCS Level II code J2850 denotes the injection of synthetic human secretin, 1 microgram. Secretin is used in specific diagnostic and therapeutic contexts, often administered parenterally in outpatient or ambulatory settings. National attention to this code centers on appropriate use, coverage determinations for diagnostic procedures, and accurate reporting of drug administration on claim lines.
Key payers considered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and billing context for J2850, typical sites of service where the drug is administered, and the role of the code in claims submission. The analysis outlines standard benchmarking areas such as utilization patterns, unit reporting, and payer coverage considerations. It also highlights where policy updates or coverage guidance commonly affect billing and reimbursement for injectable diagnostic agents.
This summary is intended for billing managers, revenue cycle staff, and clinical leaders seeking a national-level understanding of the code's purpose, common usage scenarios, and the types of payer policies that influence payment and coding practices. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2850 represents Injection, secretin, synthetic, human, 1 microgram. This code describes a pharmaceutical diagnostic or therapeutic injection based on synthetic human secretin at a 1 microgram unit dose.
-
Service type: Injectable pharmaceutical administration for diagnostic/therapeutic use
-
Typical site of service: Hospital outpatient department, ambulatory surgical center, or clinic where parenteral injections are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to a gastroenterology clinic for evaluation of suspected pancreatic exocrine insufficiency or for differentiation of gastrinoma and other causes of peptic disease when pancreatic or duodenal secretory testing is needed. The patient presents with chronic watery diarrhea, steatorrhea, unexplained weight loss, abdominal pain, or recurrent peptic ulcer disease resistant to standard therapy. After history, physical exam, and initial laboratory/imaging (e.g., abdominal CT or MRI, serum gastrin if Zollinger–Ellison is suspected), the clinician schedules a secretin stimulation test.
The procedure involves intravenous administration of J2850 (synthetic human secretin, 1 microgram) by a qualified clinician or trained nurse in an outpatient infusion suite, endoscopy unit, or hospital outpatient department. Baseline pancreatic or pancreatic-biliary samples (blood, duodenal fluid, or aspirate during endoscopic procedures) are collected prior to injection. The secretin is injected intravenously and timed collections are obtained at defined intervals to measure bicarbonate or pancreatic enzyme secretion, or to stimulate duodenal fluid for analysis. Specimens are sent to the clinical laboratory for quantitative analysis. The clinician documents indication, dose administered, route, lot number, injection time, and any immediate adverse reactions. Billing uses the HCPCS Level II code J2850 with applicable modifiers for payer-specific circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|